Genolution Inc is a Korea-based company principally engaged in the manufacture and distribution of molecular diagnostic equipment and products related to ribonucleic acid interference (RNAi) research. The Company is mainly engaged in the manufacture and sales of nucleic acid extraction reagents for extracting nucleic acids from human samples and automated nucleic acid extraction devices for automatically extracting nucleic acids from samples. The Company also provides RNAi services. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26/08/26	₩1,381.00	+0.07%	29,648
25/08/26	₩1,380.00	-0.22%	47,783
24/08/26	₩1,383.00	-0.86%	46,385
21/08/26	₩1,395.00	+0.07%	16,121
20/08/26	₩1,394.00	+0.72%	54,281

End-of-day quote Korea S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 25/08/2026			5-day change	1st Jan Change
1,380.00 ^KRW	-0.22%		-0.86%	-27.33%

02-19	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI

Market Cap	24.95B 17.99M 15.44M 14.5M 13.24M 24.99M 1.72B 25.11M 172M 66.48M 866M 67.56M 66.1M 2.87B	P/E 2024	-5.89x	P/E 2025	-2.95x
Enterprise Value	21.06B 15.19M 13.04M 12.24M 11.18M 21.1M 1.45B 21.2M 145M 56.13M 731M 57.04M 55.8M 2.42B	EV / Sales 2024	4.38x	EV / Sales 2025	3.23x
Free-Float	67.03%	Yield 2024 *	-	Yield 2025	-

02-19	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI
31/07/24	Genolution Inc. cancelled the transaction announced on May 7, 2024	CI
07/05/24	Genolution Inc. announced that it expects to receive CNY 750.00284 million in funding from RICO Asset Management Co., Ltd. and another investor	CI
09/01/24	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
09/01/24	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
09/01/24	Genolution Inc.'s Equity Buyback announced on July 10, 2023, has expired with 477,003 shares, representing 2.59% for KRW 1,989.17 million.	CI
13/10/23	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
10/07/23	Genolution Inc. announces an Equity Buyback for KRW 2,000 million worth of its shares.	CI
10/07/23	Genolution Inc. authorizes a Buyback Plan.	CI
15/05/23	Genolution Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
05/04/23	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI
05/04/23	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI

1 day	-0.22%
1 week	-0.86%
Current month	+6.48%
1 month	+5.83%
3 months	-24.01%
6 months	-23.76%
Current year	-27.33%

Genolution Inc. Stock

Stocks

A225220

KR7225220003

Biotechnology & Medical Research

Valuation : Genolution Inc.

Chart: Genolution Inc.

Latest news : Genolution Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Genolution Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

1 week	1,334	1,436
1 month	1,180	1,467
Current year	957	2,120
1 year	957	2,650
3 years	957	5,140
5 years	957	9,108.91
10 years	957	13,118.81

Manager	Title	Age	Since
Min-Ee Kim CEO	Chief Executive Officer	40	-
Ki-Ok Kim CEO	Chief Executive Officer	71	01/02/2006
Sang-Hoon Kim DFI	Director of Finance/CFO	66	-

Director	Title	Age	Since
Ki-Ok Kim BRD	Director/Board Member	71	01/02/2006
Hak-Soo Lee BRD	Director/Board Member	70	20/03/2020
Min-Ee Kim BRD	Director/Board Member	40	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/24/24 A	Sang-Hoon Kim	Others	Chief Financial Officer	404,000	2.1053%
5/19/24 A	Sang-Hoon Kim	Free	Chief Financial Officer	404,000	2.1053%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENOLUTION INC.	-0.22%	-0.86%	-46.72%	-69.09%	17.99M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-0.34%	+2.63%	+104.38%	+324.68%	4.18B
IOVANCE BIOTHERAPEUTICS, INC.	-4.27%	+1.13%	+229.80%	+31.38%	3.66B
VERACYTE, INC.	+0.57%	+4.98%	+52.36%	+74.16%	3.56B
CAREDX, INC.	+0.31%	+9.57%	+297.81%	+483.73%	2.64B
BGI GENOMICS CO., LTD.	-2.91%	+4.01%	-26.20%	-20.95%	2.33B
FREENOME, INC.	+1.52%	+2.64%	+32.48%	-	1.51B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-1.11%	+23.27%	+267.77%	-14.42%	1.33B
SEEGENE, INC.	-2.18%	+3.80%	+19.81%	+45.60%	1.06B
CURIOX BIOSYSTEMS CO., LTD	+1.68%	+22.01%	+34.48%	+180.72%	679M
Average	-0.21%	+8.29%	+96.60%	+115.09%	2.1B
Weighted average by Cap.	-0.17%	+6.43%	+125.77%	+160.07%

	2024	2025
Net sales	7.14B 5.15M 4.42M 4.15M 3.79M 7.15M 491M 7.18M 49.07M 19.01M 248M 19.32M 18.9M 820M	9.4B 6.78M 5.82M 5.46M 4.99M 9.42M 647M 9.46M 64.66M 25.06M 326M 25.47M 24.91M 1.08B
Net income	-6.83B -4.92M -4.23M -3.97M -3.62M -6.84M -470M -6.87M -46.93M -18.19M -237M -18.48M -18.08M -785M	-11.64B -8.4M -7.21M -6.76M -6.18M -11.66M -801M -11.72M -80.05M -31.02M -404M -31.53M -30.84M -1.34B
Net Debt	-8.95B -6.45M -5.54M -5.2M -4.75M -8.96M -616M -9.01M -61.54M -23.85M -311M -24.24M -23.71M -1.03B	-3.89B -2.8M -2.41M -2.26M -2.06M -3.89M -267M -3.91M -26.72M -10.35M -135M -10.52M -10.29M -447M